Up a level |
Brummendorf, Tim H, Cortes, Jorge E, Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E ORCID: 0000-0002-1261-3299, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H et al (show 9 more authors)
(2022)
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
, England.
Kantarjian, Hagop M, Hughes, Timothy P, Larson, Richard A, Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 11 more authors)
(2021)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia, 35 (2).
pp. 440-453.